



Clinical trial results:

Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC)

Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.

Summary

| | |
|--------------------------|-------------------|
| EudraCT number | 2011-003427-36 |
| Trial protocol | DE CZ HU SK |
| Global end of trial date | 30 September 2014 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 24 July 2016 |
| First version publication date | 24 July 2016 |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | M10-898 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01560104 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Abbvie Deutschland GmbH & Co.KG |
| Sponsor organisation address | AbbVie House, Vanwall Business Park, Maidenhead, Berkshire, United Kingdom, SL6-4UB |
| Public contact | Global Medical Information, AbbVie, 011 800-633-9110, |
| Scientific contact | Vincent Giranda, MD, AbbVie , Vincent.Giranda@Abbvie.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 30 September 2014 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 September 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess if the addition of oral veliparib to carboplatin and paclitaxel compared to carboplatin and paclitaxel alone in subjects with metastatic or advanced non-small cell lung cancer (NSCLC) will improve progression-free survival (PFS).

Protection of trial subjects:

All subjects entering the study had to sign an informed consent that was explained to them and questions encouraged.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 16 February 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Slovakia: 4 |
| Country: Number of subjects enrolled | Czech Republic: 10 |
| Country: Number of subjects enrolled | France: 9 |
| Country: Number of subjects enrolled | Germany: 8 |
| Country: Number of subjects enrolled | Hungary: 25 |
| Country: Number of subjects enrolled | Canada: 11 |
| Country: Number of subjects enrolled | Russian Federation: 56 |
| Country: Number of subjects enrolled | United States: 37 |
| Worldwide total number of subjects | 160 |
| EEA total number of subjects | 56 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |

| | |
|---------------------------|----|
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 92 |
| From 65 to 84 years | 68 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Adult subjects ≥ 18 years of age, with life expectancy > 12 weeks (per investigator's clinical assessment), with confirmed metastatic or advanced NSCLC not amenable to surgical resection or radiation with curative intent, and who had not received prior anticancer therapy for their metastatic NSCLC were eligible to enroll.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Subject |

Arms

| | |
|------------------------------|------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Group 1: Placebo |

Arm description:

Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|--|----------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

Placebo capsules administered orally twice a day

| | |
|--|---------------------------------|
| Investigational medicinal product name | Carboplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

| | |
|--|---------------------------------|
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Paclitaxel was administered IV over 3 hours at a dose of 200 mg/m².

| | |
|------------------|--------------------------|
| Arm title | Group 1: Veliparib 80 mg |
|------------------|--------------------------|

Arm description:

Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Veliparib |
| Investigational medicinal product code | ABT-888 |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

Veliparib capsules administered orally twice a day

| | |
|--|---------------------------------|
| Investigational medicinal product name | Carboplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

| | |
|--|---------------------------------|
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Paclitaxel was administered IV over 3 hours at a dose of 200 mg/m².

| | |
|------------------|------------------|
| Arm title | Group 2: Placebo |
|------------------|------------------|

Arm description:

Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|--|----------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

Placebo capsules administered orally twice a day

| | |
|--|---------------------------------|
| Investigational medicinal product name | Carboplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

| | |
|------------------|---------------------------|
| Arm title | Group 2: Veliparib 120 mg |
|------------------|---------------------------|

Arm description:

Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|-----------|
| Investigational medicinal product name | Veliparib |
| Investigational medicinal product code | ABT-888 |
| Other name | |
| Pharmaceutical forms | Capsule |
| Routes of administration | Oral use |

Dosage and administration details:

Veliparib capsules administered orally twice a day

| | |
|--|---------------------------------|
| Investigational medicinal product name | Carboplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Carboplatin was administered IV over approximately 15 to 30 minutes at (AUC 6 mg/mL/min)

| | |
|--|---------------------------------|
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Paclitaxel was administered IV over 3 hours at a dose of 200 mg/m².

| Number of subjects in period 1 | Group 1: Placebo | Group 1: Veliparib 80 mg | Group 2: Placebo |
|---------------------------------------|------------------|-----------------------------|------------------|
| Started | 1 | 1 | 53 |
| Received Treatment | 1 | 1 | 52 |
| Completed | 1 | 1 | 39 |
| Not completed | 0 | 0 | 14 |
| Consent withdrawn by subject | - | - | 4 |
| Other | - | - | 2 |
| Adverse event | - | - | 8 |
| Sponsor discontinued study | - | - | - |

| Number of subjects in period 1 | Group 2: Veliparib 120 mg |
|---------------------------------------|------------------------------|
| Started | 105 |
| Received Treatment | 105 |
| Completed | 75 |
| Not completed | 30 |
| Consent withdrawn by subject | 10 |
| Other | 4 |
| Adverse event | 14 |
| Sponsor discontinued study | 2 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | Group 1: Placebo |
|-----------------------|------------------|

Reporting group description:

Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|-----------------------|--------------------------|
| Reporting group title | Group 1: Veliparib 80 mg |
|-----------------------|--------------------------|

Reporting group description:

Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|-----------------------|------------------|
| Reporting group title | Group 2: Placebo |
|-----------------------|------------------|

Reporting group description:

Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|-----------------------|---------------------------|
| Reporting group title | Group 2: Veliparib 120 mg |
|-----------------------|---------------------------|

Reporting group description:

Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles

| Reporting group values | Group 1: Placebo | Group 1: Veliparib 80 mg | Group 2: Placebo |
|---|------------------|--------------------------|------------------|
| Number of subjects | 1 | 1 | 53 |
| Age categorical Units: Subjects | | | |
| < 65 years | 0 | 0 | 30 |
| ≥ 65 years | 1 | 1 | 23 |
| Gender categorical Units: Subjects | | | |
| Female | 0 | 1 | 21 |
| Male | 1 | 0 | 32 |
| Stratification Factor: Histology Units: Subjects | | | |
| Squamous cell | 1 | 0 | 25 |
| Non-squamous cell | 0 | 1 | 28 |

| Reporting group values | Group 2: Veliparib 120 mg | Total | |
|---------------------------------------|---------------------------|-------|--|
| Number of subjects | 105 | 160 | |
| Age categorical Units: Subjects | | | |
| < 65 years | 62 | 92 | |
| ≥ 65 years | 43 | 68 | |
| Gender categorical Units: Subjects | | | |
| Female | 30 | 52 | |
| Male | 75 | 108 | |

| | | | |
|----------------------------------|----|----|--|
| Stratification Factor: Histology | | | |
| Units: Subjects | | | |
| Squamous cell | 51 | 77 | |
| Non-squamous cell | 54 | 83 | |

End points

End points reporting groups

| | |
|---|---------------------------|
| Reporting group title | Group 1: Placebo |
| Reporting group description: Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m ² administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles. | |
| Reporting group title | Group 1: Veliparib 80 mg |
| Reporting group description: Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m ² administered IV on Day 3 of each 21-day cycle for up to 6 cycles. | |
| Reporting group title | Group 2: Placebo |
| Reporting group description: Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m ² administered IV on Day 3 of each 21-day cycle for up to 6 cycles. | |
| Reporting group title | Group 2: Veliparib 120 mg |
| Reporting group description: Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m ² administered IV on Day 3 of each 21-day cycle for up to 6 cycles | |

Primary: Progression-free Survival (PFS)

| | |
|--|--|
| End point title | Progression-free Survival (PFS) ^[1] |
| End point description: Progression-free survival was defined as the time from the date that the subject was randomized to the date the subject experienced an event of disease progression (as determined by the central imaging center) or to the date of death (all causes of mortality) if disease progression was not reached. All events of disease progression occurring on or before the date of the 78th PFS event were included, regardless of whether the event occurred while the subject was still taking study drug or had previously discontinued study drug. If the subject did not have disease progression nor had the subject died, the subject's data were censored at the date of the last disease assessment. If a disease progression event occurred after a subject missed 2 or more consecutive disease progression assessments, this subject was censored at the last disease progression assessment prior to the missing assessments. Efficacy analyses were performed for Group 2 subjects only. | |
| End point type | Primary |
| End point timeframe: From randomization to the data cutoff at the 78th PFS event (18 July 2013) | |

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Efficacy analyses were performed for Group 2 subjects only.

| End point values | Group 2: Placebo | Group 2: Veliparib 120 mg | | |
|----------------------------------|---------------------|---------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 53 | 105 | | |
| Units: days | | | | |
| median (confidence interval 95%) | 129 (93 to | 176 (130 to | | |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | Analysis of progression-free Survival |
| Statistical analysis description: | |
| Statistical significance was determined by a two-sided P value ≤ 0.05 . | |
| Comparison groups | Group 2: Placebo v Group 2: Veliparib 120 mg |
| Number of subjects included in analysis | 158 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.167 ^[2] |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.722 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.453 |
| upper limit | 1.149 |

Notes:

[2] - Log-rank test stratified by histology (squamous cell versus non-squamous cell).

Secondary: Overall Survival

| | |
|--|---------------------------------|
| End point title | Overall Survival ^[3] |
| End point description: | |
| Time to death for a given subject was defined as the number of days from the date that the subject was randomized to the date of the subject's death. All events of death were included, regardless of whether the event occurred while the subject was still taking study drug or after the subject discontinued study drug. If a subject had not died, the data were censored at the date when the subject was last known to be alive. | |
| End point type | Secondary |

End point timeframe:

From randomization until end of study

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Efficacy analyses were performed for Group 2 subjects only.

| End point values | Group 2: Placebo | Group 2: Veliparib 120 mg | | |
|----------------------------------|---------------------|---------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 53 | 105 | | |
| Units: days | | | | |
| median (confidence interval 95%) | 277 (165 to 374) | 357 (268 to 416) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Analysis of Overall Survival |
| Comparison groups | Group 2: Placebo v Group 2: Veliparib 120 mg |
| Number of subjects included in analysis | 158 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.266 ^[4] |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.802 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.544 |
| upper limit | 1.183 |

Notes:

[4] - Log rank test stratified by histology (squamous cell versus non-squamous cell)

Secondary: Objective Response Rate

| | |
|--|--|
| End point title | Objective Response Rate ^[5] |
| End point description: | |
| Objective response rate was defined as the proportion of subjects with complete or partial response, as determined by the central imaging center per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Confirmation was not required to determine objective response. | |
| End point type | Secondary |

End point timeframe:

From randomization until the cut-off at the 78th PFS event (18 July 2013)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Efficacy analyses were performed for Group 2 subjects only.

| End point values | Group 2: Placebo | Group 2: Veliparib 120 mg | | |
|-----------------------------------|------------------------|---------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 53 | 105 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 32.1 (19.9 to 46.3) | 32.4 (23.6 to 42.2) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Analysis of Objective Response Rate |
| Comparison groups | Group 2: Placebo v Group 2: Veliparib 120 mg |
| Number of subjects included in analysis | 158 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.992 ^[6] |
| Method | Cochran-Mantel-Haenszel |

Notes:

[6] - P value is from Cochran-Mantel-Haenszel test stratified by histology (squamous cell versus non-squamous cell).

Secondary: Duration of Overall Response

| | |
|-----------------|---|
| End point title | Duration of Overall Response ^[7] |
|-----------------|---|

End point description:

The duration of overall response for a given subject was defined as the number of days from the day the criteria were met for complete response or partial response (whichever was recorded first) to the date that progressive disease was objectively documented (by the central imaging center). If a subject was still responding, the subject's data were censored at the date of the last available disease progression assessment.

"99999" indicates data that could not be estimated.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomization until the cut-off date of the 78th PFS event (18 July 2013)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Efficacy analyses were performed for Group 2 subjects only.

| End point values | Group 2: Placebo | Group 2: Veliparib 120 mg | | |
|----------------------------------|----------------------|---------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 34 | | |
| Units: days | | | | |
| median (confidence interval 95%) | 130 (84 to 99999) | 211 (137 to 212) | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Analysis of Duration of Response |
| Comparison groups | Group 2: Placebo v Group 2: Veliparib 120 mg |
| Number of subjects included in analysis | 51 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.182 ^[8] |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.474 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.158 |
| upper limit | 1.424 |

Notes:

[8] - Log-rank P value stratified by histology (squamous cell versus non-squamous cell).

Secondary: Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20)

| | |
|-----------------|--|
| End point title | Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20) ^[9] |
|-----------------|--|

End point description:

The impact of chemotherapy-induced neuropathy (CIPN) on quality of life was assessed with the EORTC QLQ CIPN20, a 20-item questionnaire module developed to evaluate various aspects of CIPN. Each item is measured on a Likert scale ranging from 1 (not at all) to 4 (very much). The overall score was linearly transformed to a 0 to 100 scale, with higher scores representing more complaints.

The mean change from baseline was calculated using an analysis of covariance (ANCOVA) model with treatment group as the factor and the corresponding baseline value as a covariate.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and every 3 weeks until end of study

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Efficacy analyses were performed for Group 2 subjects only.

| End point values | Group 2: Placebo | Group 2: Veliparib 120 mg | | |
|--|----------------------------|---------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 48 | 94 | | |
| Units: units on a scale | | | | |
| least squares mean (confidence interval 95%) | | | | |
| Cycle 2 Day 1 (N = 48, 94) | 4.009 (1.2408 to 6.777) | 4.413 (2.4348 to 6.3904) | | |
| Cycle 3 Day 1 (N = 44, 85) | 4.916 (1.5535 to 8.278) | 6.555 (4.1365 to 8.973) | | |
| Cycle 4 Day 1 (N = 39, 77) | 8.414 (4.4077 to 12.4198) | 6.767 (3.9161 to 9.6176) | | |
| Cycle 5 Day 1 (N = 35, 67) | 8.509 (4.5908 to 12.4274) | 8.629 (5.7978 to 11.4611) | | |
| Cycle 6 Day 1 (N = 29, 60) | 10.942 (5.6451 to 16.2396) | 12.321 (8.6382 to 16.0036) | | |
| Cycle 7 Day 1 (N = 25, 52) | 13.576 (7.4149 to 19.7367) | 15.597 (11.325 to 19.8684) | | |
| Cycle 8 Day 1 (N = 16, 41) | 9.505 (1.2527 to 17.7569) | 14.034 (8.9009 to 19.1678) | | |
| Cycle 9 Day 1 (N = 16, 34) | 5.452 (-2.1343 to 13.0386) | 15.426 (10.2566 to 20.5955) | | |

| | | | | |
|-----------------------------|----------------------------|---------------------------|--|--|
| Cycle 10 Day 1 (N = 9, 27) | 9.854 (-0.966 to 20.6744) | 15.19 (8.9632 to 21.4174) | | |
| Cycle 11 day 1 (N = 9, 21) | 3.72 (-3.7312 to 11.1718) | 9.602 (4.7245 to 14.4801) | | |
| Cycle 12 Day 1 (N = 8, 18) | 11.223 (2.0688 to 20.377) | 8.344 (2.255 to 14.4336) | | |
| Cycle 13 Day 1 (N = 7, 12) | 3.487 (-5.4678 to 12.4409) | 8.652 (1.8145 to 15.4905) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Grade 3 or 4 Treatment-Emergent Adverse Events of Peripheral Neuropathy

| | |
|-----------------|---|
| End point title | Number of Participants With Grade 3 or 4 Treatment-Emergent Adverse Events of Peripheral Neuropathy ^[10] |
|-----------------|---|

End point description:

Chemotherapy-induced peripheral neuropathy was assessed by the investigator utilizing the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grading for neuropathy.

Grade 3 or 4 treatment-emergent adverse events of peripheral neuropathy were identified based on a standardized Medical Dictionary for Regulatory Activities (SMQ) (broad search).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 of each cycle and at the final visit

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Efficacy analyses were performed for Group 2 subjects only.

| End point values | Group 2: Placebo | Group 2: Veliparib 120 mg | | |
|-----------------------------|------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 52 | 105 | | |
| Units: participants | 2 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose until 30 days after last dose. Median treatment duration was 42 days for Group 1 participants, 40.5 days for Group 2 placebo participants and 36 days for Group 2 veliparib participants.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 17.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | Group 1: Placebo |
|-----------------------|------------------|

Reporting group description:

Participants enrolled under the original protocol received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered intravenously (IV) on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|-----------------------|--------------------------|
| Reporting group title | Group 1: Veliparib 80 mg |
|-----------------------|--------------------------|

Reporting group description:

Participants enrolled under the original protocol received 80 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|-----------------------|------------------|
| Reporting group title | Group 2: Placebo |
|-----------------------|------------------|

Reporting group description:

Participants enrolled under protocol amendment 2 received placebo capsules twice a day (BID) on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles.

| | |
|-----------------------|---------------------------|
| Reporting group title | Group 2: Veliparib 120 mg |
|-----------------------|---------------------------|

Reporting group description:

Participants enrolled under protocol amendment 2 received 120 mg veliparib capsules BID on Days 1 through 7 plus carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered IV on Day 3 of each 21-day cycle for up to 6 cycles

| Serious adverse events | Group 1: Placebo | Group 1: Veliparib 80 mg | Group 2: Placebo |
|---|------------------|--------------------------|------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 12 / 52 (23.08%) |
| number of deaths (all causes) | 1 | 0 | 39 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Malignant Neoplasm Progression | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Malignant Pleural Effusion | | | |

| | | | |
|--|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Non-Small Cell Lung Cancer | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Embolism | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Superior Vena Cava Occlusion | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vena Cava Thrombosis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Anaphylactic Reaction | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Drug Hypersensitivity | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|---------------|----------------|
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary Embolism | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Pulmonary Haemorrhage | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Respiratory Distress | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Failure | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Delirium | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Weight Decreased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute Myocardial Infarction | | | |

| | | | |
|---|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Cardiac Failure Congestive | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Ischaemic Stroke | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile Neutropenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |

| | | | |
|---|---------------|---------------|----------------|
| Colitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal Haemorrhage | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Renal Failure | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal Failure Acute | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|---------------|----------------|
| Lung Abscess | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perirectal Abscess | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|------------------------------|--|--|
| Serious adverse events | Group 2: Veliparib 120 mg | | |
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 28 / 105 (26.67%) | | |
| number of deaths (all causes) | 74 | | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Malignant Neoplasm Progression | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Malignant Pleural Effusion | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Non-Small Cell Lung Cancer | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Vascular disorders | | | |
| Embolism | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Superior Vena Cava Occlusion | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Vena Cava Thrombosis | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| Anaphylactic Reaction | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Drug Hypersensitivity | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary Embolism | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary Haemorrhage | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Respiratory Distress | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory Failure | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Psychiatric disorders | | | |
| Delirium | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| Weight Decreased | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Acute Myocardial Infarction | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac Failure Congestive | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Ischaemic Stroke | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 3 / 105 (2.86%) | | |
| occurrences causally related to treatment / all | 1 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Febrile Neutropenia | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Leukopenia | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Thrombocytopenia | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Colitis | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal Haemorrhage | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Nausea | | | |
| subjects affected / exposed | 3 / 105 (2.86%) | | |
| occurrences causally related to treatment / all | 1 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Renal Failure | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal Failure Acute | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------------------------|--|--|
| Infections and infestations Bronchitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 2 / 105 (1.90%) 0 / 2 0 / 0 | | |
| Lung Abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 1 / 105 (0.95%) 0 / 1 0 / 0 | | |
| Perirectal Abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 1 / 105 (0.95%) 0 / 1 0 / 0 | | |
| Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 1 / 105 (0.95%) 0 / 1 0 / 0 | | |
| Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 1 / 105 (0.95%) 1 / 1 0 / 0 | | |
| Urinary Tract Infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 105 (0.00%) 0 / 0 0 / 0 | | |
| Metabolism and nutrition disorders Hyponatraemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 1 / 105 (0.95%) 0 / 1 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Group 1: Placebo | Group 1: Veliparib 80 mg | Group 2: Placebo |
|---|------------------|-----------------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 1 / 1 (100.00%) | 41 / 52 (78.85%) |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 1 | 0 | 3 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 1 / 1 (100.00%) | 13 / 52 (25.00%) |
| occurrences (all) | 1 | 1 | 15 |
| Mucosal Inflammation | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 4 |
| Oedema Peripheral | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 1 | 0 | 5 |
| Pain | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 5 |
| Immune system disorders | | | |
| Drug Hypersensitivity | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 3 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 8 / 52 (15.38%) |
| occurrences (all) | 1 | 0 | 8 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 1 | 0 | 6 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|-------------------------------|-----------------|---------------|------------------|
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 5 |
| Investigations | | | |
| Platelet Count Decreased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 9 |
| Weight Decreased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Cardiac disorders | | | |
| Cardiac Failure Congestive | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Headache | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Neuropathy Peripheral | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 13 / 52 (25.00%) |
| occurrences (all) | 1 | 0 | 19 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Peripheral Sensory Neuropathy | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 1 | 0 | 7 |
| Polyneuropathy | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 5 |

| | | | |
|--|-----------------|-----------------|------------------|
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 21 / 52 (40.38%) |
| occurrences (all) | 1 | 0 | 36 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 1 / 1 (100.00%) | 15 / 52 (28.85%) |
| occurrences (all) | 1 | 1 | 28 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 8 / 52 (15.38%) |
| occurrences (all) | 0 | 1 | 16 |
| Gastrointestinal disorders | | | |
| Constipation | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 7 / 52 (13.46%) |
| occurrences (all) | 0 | 1 | 8 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 8 / 52 (15.38%) |
| occurrences (all) | 1 | 0 | 9 |
| Nausea | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 13 / 52 (25.00%) |
| occurrences (all) | 0 | 1 | 18 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 5 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 22 / 52 (42.31%) |
| occurrences (all) | 0 | 1 | 26 |
| Pruritus | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 2 / 52 (3.85%) 2 |
| Rash Pruritic subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 1 / 52 (1.92%) 1 |
| Renal and urinary disorders Pollakiuria subjects affected / exposed occurrences (all) | 1 / 1 (100.00%) 1 | 0 / 1 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 7 / 52 (13.46%) 7 |
| Back Pain subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 3 / 52 (5.77%) 4 |
| Bone Pain subjects affected / exposed occurrences (all) | 1 / 1 (100.00%) 1 | 0 / 1 (0.00%) 0 | 2 / 52 (3.85%) 2 |
| Musculoskeletal Chest Pain subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 0 / 52 (0.00%) 0 |
| Musculoskeletal Pain subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 3 / 52 (5.77%) 4 |
| Myalgia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 4 / 52 (7.69%) 7 |
| Pain In Extremity subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 6 / 52 (11.54%) 9 |
| Infections and infestations Lobar Pneumonia subjects affected / exposed occurrences (all) | 1 / 1 (100.00%) 1 | 0 / 1 (0.00%) 0 | 1 / 52 (1.92%) 1 |
| Respiratory Tract Infection | | | |

| | | | |
|------------------------------------|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Metabolism and nutrition disorders | | | |
| Decreased Appetite | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 9 / 52 (17.31%) |
| occurrences (all) | 0 | 0 | 12 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 3 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 5 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 8 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 6 |

| | | | |
|--|------------------------------|--|--|
| Non-serious adverse events | Group 2: Veliparib 120 mg | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 92 / 105 (87.62%) | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 9 / 105 (8.57%) | | |
| occurrences (all) | 13 | | |
| Fatigue | | | |
| subjects affected / exposed | 23 / 105 (21.90%) | | |
| occurrences (all) | 39 | | |
| Mucosal Inflammation | | | |

| | | | |
|---|--|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Oedema Peripheral</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 105 (0.95%)</p> <p>3</p> <p>6 / 105 (5.71%)</p> <p>10</p> <p>2 / 105 (1.90%)</p> <p>3</p> <p>5 / 105 (4.76%)</p> <p>6</p> | | |
| <p>Immune system disorders</p> <p>Drug Hypersensitivity</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>8 / 105 (7.62%)</p> <p>9</p> | | |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Haemoptysis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>8 / 105 (7.62%)</p> <p>9</p> <p>15 / 105 (14.29%)</p> <p>17</p> <p>6 / 105 (5.71%)</p> <p>7</p> | | |
| <p>Psychiatric disorders</p> <p>Insomnia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>10 / 105 (9.52%)</p> <p>13</p> | | |
| <p>Investigations</p> <p>Platelet Count Decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight Decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>4 / 105 (3.81%)</p> <p>5</p> <p>7 / 105 (6.67%)</p> <p>8</p> | | |

| | | | |
|--------------------------------------|-------------------|--|--|
| Cardiac disorders | | | |
| Cardiac Failure Congestive | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 7 / 105 (6.67%) | | |
| occurrences (all) | 9 | | |
| Dysgeusia | | | |
| subjects affected / exposed | 6 / 105 (5.71%) | | |
| occurrences (all) | 7 | | |
| Headache | | | |
| subjects affected / exposed | 8 / 105 (7.62%) | | |
| occurrences (all) | 10 | | |
| Neuropathy Peripheral | | | |
| subjects affected / exposed | 25 / 105 (23.81%) | | |
| occurrences (all) | 38 | | |
| Paraesthesia | | | |
| subjects affected / exposed | 4 / 105 (3.81%) | | |
| occurrences (all) | 6 | | |
| Peripheral Sensory Neuropathy | | | |
| subjects affected / exposed | 8 / 105 (7.62%) | | |
| occurrences (all) | 13 | | |
| Polyneuropathy | | | |
| subjects affected / exposed | 3 / 105 (2.86%) | | |
| occurrences (all) | 4 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 30 / 105 (28.57%) | | |
| occurrences (all) | 44 | | |
| Leukopenia | | | |
| subjects affected / exposed | 10 / 105 (9.52%) | | |
| occurrences (all) | 13 | | |
| Neutropenia | | | |
| subjects affected / exposed | 37 / 105 (35.24%) | | |
| occurrences (all) | 55 | | |
| Thrombocytopenia | | | |

| | | | |
|---|-------------------|--|--|
| subjects affected / exposed | 11 / 105 (10.48%) | | |
| occurrences (all) | 20 | | |
| Gastrointestinal disorders | | | |
| Constipation | | | |
| subjects affected / exposed | 9 / 105 (8.57%) | | |
| occurrences (all) | 12 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 13 / 105 (12.38%) | | |
| occurrences (all) | 16 | | |
| Nausea | | | |
| subjects affected / exposed | 26 / 105 (24.76%) | | |
| occurrences (all) | 42 | | |
| Stomatitis | | | |
| subjects affected / exposed | 3 / 105 (2.86%) | | |
| occurrences (all) | 3 | | |
| Vomiting | | | |
| subjects affected / exposed | 5 / 105 (4.76%) | | |
| occurrences (all) | 5 | | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 41 / 105 (39.05%) | | |
| occurrences (all) | 50 | | |
| Pruritus | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences (all) | 1 | | |
| Rash | | | |
| subjects affected / exposed | 1 / 105 (0.95%) | | |
| occurrences (all) | 1 | | |
| Rash Pruritic | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences (all) | 0 | | |
| Renal and urinary disorders | | | |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|------------------------------------|-------------------|--|--|
| Arthralgia | | | |
| subjects affected / exposed | 20 / 105 (19.05%) | | |
| occurrences (all) | 31 | | |
| Back Pain | | | |
| subjects affected / exposed | 8 / 105 (7.62%) | | |
| occurrences (all) | 8 | | |
| Bone Pain | | | |
| subjects affected / exposed | 5 / 105 (4.76%) | | |
| occurrences (all) | 9 | | |
| Musculoskeletal Chest Pain | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences (all) | 3 | | |
| Musculoskeletal Pain | | | |
| subjects affected / exposed | 4 / 105 (3.81%) | | |
| occurrences (all) | 5 | | |
| Myalgia | | | |
| subjects affected / exposed | 13 / 105 (12.38%) | | |
| occurrences (all) | 29 | | |
| Pain In Extremity | | | |
| subjects affected / exposed | 12 / 105 (11.43%) | | |
| occurrences (all) | 14 | | |
| Infections and infestations | | | |
| Lobar Pneumonia | | | |
| subjects affected / exposed | 0 / 105 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory Tract Infection | | | |
| subjects affected / exposed | 4 / 105 (3.81%) | | |
| occurrences (all) | 4 | | |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 2 / 105 (1.90%) | | |
| occurrences (all) | 2 | | |
| Metabolism and nutrition disorders | | | |
| Decreased Appetite | | | |
| subjects affected / exposed | 14 / 105 (13.33%) | | |
| occurrences (all) | 19 | | |
| Hyperglycaemia | | | |

| | | | |
|-----------------------------|------------------|--|--|
| subjects affected / exposed | 6 / 105 (5.71%) | | |
| occurrences (all) | 8 | | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 5 / 105 (4.76%) | | |
| occurrences (all) | 7 | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 6 / 105 (5.71%) | | |
| occurrences (all) | 6 | | |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 10 / 105 (9.52%) | | |
| occurrences (all) | 12 | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 5 / 105 (4.76%) | | |
| occurrences (all) | 7 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 29 February 2012 | <p>The primary purpose of this amendment was to update the recommended Phase 2 dose to 120 mg BID veliparib after reviewing recent data from Studies GOG 9923 and CTEP 7967. The 120 mg BID dose of veliparib was determined to be the recommended Phase 2 dose based on data from Study GOG 9923 (Phase 1 dose-escalation study in subjects with advanced or metastatic ovarian cancer). Changes included the following:</p> <ul style="list-style-type: none">• Updated veliparib/placebo dose to 120 mg BID throughout the protocol. Subjects enrolled under the original protocol received a starting dose of 80 mg BID veliparib/placebo and subjects enrolled under Amendment No. 1 were to receive a starting dose of 120 mg BID veliparib/placebo.• Clarified Section 3.5, Study Rationale, and Section 5.6.4, Selection of Doses in the Study, to substantiate the rationale for selecting the 120 mg BID veliparib/placebo dose.• Revised details of the IDMC safety review.• Veliparib/placebo dose reduction guidelines were added in Section 5.7 for subjects starting at 120 mg BID veliparib/placebo.• Revised the approximate number of subjects enrolled to 135 across approximately 50 sites.• Added further detail to Section 5.2.3.2, Concomitant Therapy.• Clarified several study activities in Table 2 (Study Activities).• Added a complete blood count draw on C1D17.• Corrected timing of serum pregnancy test to 14 days prior to C1D1 to clarify previous inconsistency within the protocol.• Added clarification to the smoking status definitions for stratification. |
| 29 April 2013 | <p>The primary purpose of this amendment was to increase enrollment to approximately 150 subjects. Due to the number of progression events reported by investigators in the study thus far, the target sample size was increased to maintain timing of the efficacy and safety evaluation that was to commence once 78 PFS events had been observed. Additional changes included:</p> <ul style="list-style-type: none">• Updated AbbVie medical monitor contact.• Updated Section 3.4.3, Toxicology to reflect the most current data.• Revised visit schedule for subjects who stopped treatment or completed maximum number of treatment cycles prior to reaching an event of disease progression from every 3 weeks to every 6 weeks.• Added request for an unscheduled tumor assessment to be performed if the investigator anticipated subject discontinuation for a reason other than radiographic progression (unless a scan had been performed within the last 2 weeks).• Added footnote to Table 3 regarding the archived tissue sample collection time to reflect corresponding lab manual.• Updated Section 5.2.3.2, Concomitant Therapy to clarify excluded radiation therapy.• Revised Section 5.3.1.3, Blood Samples for Pharmacodynamic Analyses to allow for cytology sample collection in certain cases where there was no archived tissue sample available.• Clarification that subsequent IDMC meetings could have been requested by AbbVie (as indicated in the IDMC charter).• Added guidance to Section 5.7.1 for subjects who commenced a cycle but could not receive chemotherapy on Day 3 due to an adverse event.• Added clarifications throughout Section 8.0, Statistical Methods and Determination of Sample Size.• Changed all instances of Abbott or Abbott Laboratories found within the protocol to AbbVie except if outside documents were referenced (e.g., Investigator's Brochure, references).• Changed the manufacturer of drug supply in Section 5.5.2, Table 6, Identity of Investigational Product from Abbott to AbbVie/Abbott. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported